Daiichi Sankyo has inked a commercial license agreement for the use of the Red/ET recombination technology from Gene Bridges. The Red/ET recombination technology is a method for generating targeting vectors or modifying E. coli chromosomes.
 
According to Gene Bridges, recombineering with Red/ET allows cloning, subcloning, and modification of DNA at any chosen position. It permits precise engineering of DNA molecules of any size, including large ones such as BACs or the E.coli chromosome.


 

Previous articleStemgent Inks Deal to Co-Market CellDesign’s Adipocyte Research Products
Next articleNeuraltus Closes $17M Series A Financing